PRINCETON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc. a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced the launch of a new tool to help healthcare providers (HCPs) ...
On Monday, Soligenix, Inc. (NASDAQ:SNGX) said it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL). The ...
Late-stage biopharmaceutical company Soligenix, Inc. SNGX focuses on developing treatments for rare and underserved diseases. Primarily, the firm specializes in providing groundbreaking treatments for ...
Study Supported by $2.6 Million FDA Orphan Products Development Grant "We are pleased with these recent study results and that the FDA is continuing to financially support the HyBryte™ program, giving ...
(RTTNews) - Citius Oncology, Inc. (CTOR), the oncology subsidiary of Citius Pharmaceuticals Inc. (CTXR) announced the U.S. commercial launch of LYMPHIR, a new immunotherapy for adults with relapsed or ...
PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback